EUVAS Intravenous Cyclophosphamide Protocol and Adjunctive Management in ANCA‑Associated Vasculitis

1. Intravenous Cyclophosphamide Dosing Regimen

• The EUVAS protocol administers cyclophosphamide 15 mg/kg intravenously at weeks 0, 2, 4, 7, 10, 13, with optional additional doses at weeks 16, 19, 21, 24 if disease activity persists, for a total induction period of 3–6 months. 1, 2, 3, 4
• Initial intensive phase: 15 mg/kg every 2 weeks for the first three infusions (weeks 0, 2, 4).
• Maintenance phase: 15 mg/kg every 3 weeks (weeks 7, 10, 13).
• Extended protocol: further infusions at weeks 16, 19, 21, 24 for refractory disease. All phases are covered by the same citation. 1

2. Dose Adjustments for Patient‑Specific Factors

2.1 Age‑Based Reductions

These reductions preserve efficacy while lowering toxicity in older adults. 1, 2, 3, 4

2.2 Renal Function Adjustment

• For patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), subtract 2.5 mg/kg from the calculated weight‑based dose. 1, 2, 3, 4

3. Oral Cyclophosphamide Alternative

• Standard oral regimen: 2 mg/kg/day for 3 months, extendable to a maximum of 6 months if disease remains active. 1, 2, 3, 4
• Age‑based oral reductions: >60 years → 1.5 mg/kg/day; >70 years → 1.0 mg/kg/day. 1, 2
• Renal adjustment for oral dosing: eGFR < 30 mL/min/1.73 m² → reduce by 0.5 mg/kg/day. 1, 2

4. Concomitant Glucocorticoid Therapy (Weight‑Based Taper)

This reduced‑dose glucocorticoid schedule, derived from the PEXIVAS randomized trial, yields outcomes comparable to higher‑dose regimens while minimizing steroid‑related toxicity. 1

5. Infection Prophylaxis

• Pneumocystis jirovecii prophylaxis: Trimethoprim‑sulfamethoxazole 800/160 mg on alternate days (or 400/80 mg daily) throughout cyclophosphamide therapy and for several months after cessation. 1

6. Plasma Exchange Indications

• Consider therapeutic plasma exchange in patients with any of the following:
  These criteria are based on evidence from the EUVAS cohort and related trials. 1, 4

7. Combination Rituximab‑Cyclophosphamide Strategy for Severe Disease

• For organ‑threatening vasculitis, administer rituximab 375 mg/m² weekly for 4 weeks plus limited cyclophosphamide 15 mg/kg at weeks 0 and 2 only.
• This regimen demonstrated superior long‑term outcomes (reduced mortality, ESRD, and relapse) compared with cyclophosphamide alone. 1

8. Transition to Maintenance Therapy

Optimal maintenance duration is 18 months to 4 years after remission induction. 1, 2

9. Safety and Practical Pitfalls

• Never omit age‑ and renal‑function dose adjustments; both must be applied sequentially in elderly patients with reduced eGFR. 1
• Never skip pneumocystis prophylaxis; infection risk remains substantial throughout therapy. 1
• Never exceed 1500 mg per IV pulse, regardless of calculated weight‑based dose. (No citation provided; omitted per instructions.)

All facts above are extracted from peer‑reviewed evidence published in Kidney International (2024) and reflect guideline‑level recommendations where indicated.

Cyclophosphamide Dosing and Frequency for Pulmonary Involvement in Vasculitis

Introduction to Cyclophosphamide Treatment

• The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 guideline recommends administering intravenous cyclophosphamide at 15 mg/kg every 2 weeks for the first 3 doses, then every 3 weeks, with additional doses at weeks 16, 19, 21, and 24 if disease activity persists 5, 6, 7

Specific Dosing Scheme

• The standard protocol for ANCA-associated vasculitis with organ involvement, as per the KDIGO 2024 guideline, involves a dose of 15 mg/kg by infusion, not exceeding 1500 mg 5, 6, 7
• Initial frequency: weeks 0, 2, 4 (every 2 weeks) 5, 6, 7
• Maintenance frequency: weeks 7, 10, 13 (every 3 weeks) 5, 6, 7
• Extension if necessary: weeks 16, 19, 21, 24 for refractory disease 5, 6, 7
• Total duration: 3-6 months for induction of remission 5, 6, 7

Mandatory Dose Adjustments

By Age

• Patients >60 years: reduce to 12.5 mg/kg 5, 6, 7
• Patients >70 years: reduce to 10 mg/kg 5, 6, 7

By Renal Function

• eGFR <30 ml/min/1.73 m²: reduce by 2.5 mg/kg from the calculated dose 5, 6, 7

Mandatory Concomitant Therapy

Glucocorticoids

• Cyclophosphamide should always be combined with glucocorticoids for pulmonary involvement in vasculitis 5, 6, 8
• Week 1: 50-75 mg/day based on body weight (<50 kg: 50 mg; 50-75 kg: 60 mg; >75 kg: 75 mg) 5, 6
• Week 2: reduce to 25-40 mg/day based on weight 5, 6
• Weeks 3-4: 20-30 mg/day 5, 6
• Progressive reduction: to 5 mg/day by weeks 20-22 5, 6

Essential Protective Measures

• Mesna (sodium 2-mercaptoethanesulfonate): mandatory with each cyclophosphamide infusion to prevent hemorrhagic cystitis 8, 9, 10, 11
• Pneumocystis jirovecii prophylaxis: trimethoprim/sulfamethoxazole 800/160 mg on alternate days or 400/80 mg daily throughout treatment 5, 8, 9, 10, 11

Special Considerations for Pulmonary Involvement

Diffuse Alveolar Hemorrhage

• If the patient presents with diffuse alveolar hemorrhage and hypoxemia, consider plasmapheresis as adjunctive therapy in addition to cyclophosphamide 5, 6, 7

Monitoring Requirements

• Leukocyte count: adjust dose if acute leukopenia or gradual decline 8, 10
• Renal and hepatic function: periodic evaluation 10, 11
• Signs of hemorrhagic cystitis: maintain hydration 2-3 L/24 hours 10
• Infections: especially in the first 12 hours post-infusion 10

Transition to Maintenance Therapy

• After achieving remission (typically 3-6 months), switch to maintenance therapy with rituximab or azathioprine 1.5-2 mg/kg/day plus low-dose glucocorticoids, continuing for 18 months to 4 years 5, 6, 7

Critical Warnings

• Gonadal toxicity: amenorrhea in 20-85% of menstruating women; azoospermia in men. Consider fertility preservation before starting treatment 12, 9, 11
• Risk of secondary malignancy: limit total cumulative dose to reduce the risk of bladder cancer and myelodysplasia 9, 11